| Assessment Status | Assessment Process Complete |
| HTA ID | - |
| Drug | Pirfenidone |
| Brand | Esbriet® |
| Indication | For the treatment of mild to moderate idiopathic pulmonary fibrosis. |
| Assessment Process | |
| Rapid review commissioned | 15/12/2011 |
| Rapid review completed | 05/01/2012 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
| Full submission received from Applicant | 26/11/2012 |
| NCPE assessment completed | 20/03/2013 |
| NCPE assessment outcome | Reimbursement not Recommended |
The NCPE believe that, at the submitted price, pirfenidone is not cost-effective for the treatment of patients with mild to moderate Idiopathic Pulmonary Fibrosis.
The HSE has approved reimbursement following confidential price negotiations March 2015.
